Effect of Haloperidol and Risperidone to modify levels of markers of inflammation in blood in Schizophrenia Spectrum and other Psychotic Disorders

Not Applicable

Completed

• Conditions: Health Condition 1: F20-F29- Schizophrenia, schizotypal, delusional, and other non-mood psychotic disorders

• Registration Number: CTRI/2021/05/033890
• Lead Sponsor: Government Medical College and Hospital Sector Chandigarh

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 19 December 2023

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 48

Inclusion Criteria

1) Patients with a diagnosis of ‘Schizophrenia Spectrum and Other Psychotic disorder’ as per Diagnostic and Statistical Manual of Mental Disorders (DSM-5) given by American Psychiatric Association

2) Age group 18-65 years

3) Drug naïve patients

4) Any gender

5) Patients having the capacity (as per section 4 of the Mental Healthcare Act 2017) to give written consent or Nominated Representative (NR) agreeing to give written consent when patient does not have adequate capacity.

Exclusion Criteria

1) Patients with substance abuse (in the past 6 months) except caffeine and nicotine

2) Patients with history of hypersensitivity to Haloperidol or Risperidone

3) Having infectious disease, physical injury and autoimmune diseases, using anti- inflammatory drugs, corticosteroids or antibiotics in the recent 4 weeks

4) Pregnant and lactating patient

5) Patients at high risk of suicide

Study & Design

• Study Type: Interventional
• Study Design: Not specified